Recombinant Human CD19 Protein, DDK/His-tagged
Cat.No. : | CD19-409H |
Product Overview : | Recombinant Human CD19(Pro20 – Lys291), transcript variant 2, fused with DDK/His tag at C-terminal was expressed in HEK293. |
- Specification
- Gene Information
- Related Products
Description : | Lymphocytes proliferate and differentiate in response to various concentrations of different antigens. The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors. This gene encodes a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. |
Source : | HEK293 |
Species : | Human |
Tag : | DDK/His |
Form : | 1 x PBS, pH7.4, 10% glycerol. |
Molecular Mass : | 32 kDa |
Protein length : | Pro20 – Lys291 |
Purity : | > 80% as determined by SDS-PAGE and Coomassie blue staining |
Concentration : | >50 ug/mL as determined by microplate BCA method |
Gene Name : | CD19 CD19 molecule [ Homo sapiens ] |
Official Symbol : | CD19 |
Synonyms : | CD19; CD19 molecule; CD19 antigen; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4; B4; CVID3; MGC12802; |
Gene ID : | 930 |
mRNA Refseq : | NM_001770 |
Protein Refseq : | NP_001761 |
MIM : | 107265 |
UniProt ID : | P15391 |
Products Types
◆ Recombinant Protein | ||
CD19-05H | Active Recombinant Human CD19 Protein, Fc-tagged, Alexa Fluor® 488 conjugated | +Inquiry |
CD19-315C | Recombinant Cynomolgus CD19 Protein, Fc-tagged | +Inquiry |
CD19-130H | Recombinant Human CD19 Protein, Fc-tagged | +Inquiry |
CD19-129H | Recombinant Human CD19 Protein, His-tagged | +Inquiry |
CD19-08H | Active Recombinant Human CD19 Protein, Fc-tagged, Atto 647N conjugated | +Inquiry |
◆ Lysates | ||
CD19-2164MCL | Recombinant Mouse CD19 cell lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (5)
Ask a questionCAR-T cells are engineered to express a receptor that recognizes CD19 on the surface of cancerous B cells. When they encounter these cells, they destroy them.
CD19 deficiencies can lead to primary immunodeficiencies, making individuals more susceptible to infections.
Side effects may include cytokine release syndrome (CRS), neurologic toxicity, and long-term B-cell aplasia.
CAR-T cell therapy is used to treat B-cell malignancies such as acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma.
CAR-T cell therapy has shown remarkable effectiveness in inducing remissions in patients with CD19-positive malignancies, particularly in those who have relapsed or failed conventional treatments.
Customer Reviews (3)
Write a reviewThe manufacturer of CD19 protein has consistently provided outstanding technical support that has surpassed my expectations.
This protein demonstrates remarkable purity, stability, and specificity, ensuring utmost accuracy and reproducibility in my research endeavors.
Their dedication to customer satisfaction has been instrumental in overcoming obstacles and achieving successful results in my experiments.
Ask a Question for All CD19 Products
Required fields are marked with *
My Review for All CD19 Products
Required fields are marked with *
Inquiry Basket